Tehran University of Medical Sciences

Science Communicator Platform

Share By
Impact of Conditioning Regimen on Outcomes of Young Aml Patients ( < 40 Years) Undergoing Hct in Complete Remission, With Transplant Conditioning Intensity Score of 3.5-4.0. a Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Publisher



Maffini E ; Ngoya M ; Houhou M ; Benakli M ; Bahar B ; Aljurf M ; Halahleh K ; Peffault De Latour R ; Blau I W ; Clark A ; Flynn C ; Remenyi P P ; Maroto M L ; Yakoub Agha I Show All Authors
Authors
  1. Maffini E
  2. Ngoya M
  3. Houhou M
  4. Benakli M
  5. Bahar B
  6. Aljurf M
  7. Halahleh K
  8. Peffault De Latour R
  9. Blau I W
  10. Clark A
  11. Flynn C
  12. Remenyi P P
  13. Maroto M L
  14. Yakoub Agha I
  15. Sengeloev H
  16. Castilla Llorente C
  17. Nicholson E
  18. Salmenniemi U
  19. Vrhovac R
  20. Passweg J
  21. Eder M
  22. Daguindau E
  23. Spyridonidis A
  24. Nagler A
  25. Ciceri F
  26. Mohty M

Source: Bone Marrow Transplantation Published:2026


Abstract

The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (n = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) n = 219, Bu-Flu (n = 1100), and Bu-cyclophosphamide (Cy) (n = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57–0.92, p = 0.008; HR 0.78, 95% CI 0.64–0.94, p = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, p = 0.02; HR 0.67, 95% CI 0.47–0.94, p = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63–0.95, p = 0.01), and TBF (HR 0.68, 95% CI 0.47–0.99, p = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted. © The Author(s), under exclusive licence to Springer Nature Limited 2026.